Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SGMS2 | Q8NHU3 | 3/20 | 0.49 |
| ▸ | LRRK2 | Q5S007 | 5/20 | 0.42 |
| ▸ | PPIA | P62937 | 1/20 | 0.41 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.40 |
| ▸ | ALB | P02768 | 1/20 | 0.39 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.39 |
| ▸ | VNN1 | O95497 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | GPR132 | Q9UNW8 | 2/20 | 0.38 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
| ▸ | MET | P08581 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6814183 | 0.91 | MRGPRX4 (0.43) | SGMS2PPIAALBMRGPRX4LMNA | |
| SCHEMBL6710120 | 0.85 | SGMS2 (0.42) | SGMS2LRRK2PPIACHEK1VNN1 | |
| SCHEMBL6830475 | 0.84 | ALB (0.46) | ALBLMNA | |
| SCHEMBL6708983 | 0.83 | SGMS2 (0.41) | SGMS2LRRK2PPIACHEK1VNN1 | |
| SCHEMBL6833983 | 0.83 | AKR1C2 (0.42) | ALBLMNABRD4MET | |
| SCHEMBL6834153 | 0.83 | PLK1 (0.44) | ALBLMNA | |
| SCHEMBL6833872 | 0.83 | KDM1A (0.43) | ALBLMNA | |
| SCHEMBL6834587 | 0.82 | CYP1A2 (0.38) | SGMS2ALBMRGPRX4LMNACYP1A2 | |
| SCHEMBL6834068 | 0.82 | ALB (0.43) | ALBMRGPRX4LMNA | |
| SCHEMBL6830121 | 0.82 | ALB (0.40) | ALBMRGPRX4LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040110802-A1 | Antibacterial benzoic acid derivatives | PHARMACIA & UPJOHN COMPANY | 2004-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110802-A1 | Antibacterial benzoic acid derivatives | GABRD, GABBR1, GABRA1 | SGMS2 4791/4885LRRK2 4720/4885PPIA 4193/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.